search
Back to results

Secondary Prevention of Small Subcortical Strokes Trial (SPS3)

Primary Purpose

Cerebrovascular Accident, Hypertension

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
aspirin
clopidogrel
Target of Blood Pressure
placebo
Sponsored by
University of British Columbia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cerebrovascular Accident focused on measuring stroke, hypertension, high blood pressure, lacunar stroke, subcortical stroke, aspirin, clopidogrel

Eligibility Criteria

30 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

INCLUSION: Small subcortical ischemic stroke or subcortical TIA. Inclusion criteria are based on TOAST criteria supplemented by required MRI data. All of the following criteria must be met: One of the lacunar stroke clinical syndromes (adapted from Fisher) lasting > 24 hrs within the past 6 months Absence of signs or symptoms of cortical dysfunction such as aphasia, apraxia, agnosia, agraphia, homonymous visual field defect, etc. No ipsilateral cervical carotid stenosis (≥50%) by a reliable imaging modality done in an approved laboratory since the qualifying small subcortical stroke (S3), if hemispheric. No major-risk cardioembolic sources requiring anticoagulation or other specific therapy. Minor-risk cardioembolic sources will be permitted if anticoagulation is not prescribed by the patient's primary care physician. Subcortical TIA with corresponding lesion on DWI. MRI evidence of S3: a. Presence of an S3 (1.5 and 2 cm in diameter corresponding to the qualifying event on DWI; when TIA, ADC image must confirm lesion or T2/FLAIR (hyperintense lesions) (required for all brainstem events) OR multiple S3s on FLAIR/TI(<1.5 cm in diameter) (hypointense lesions) b. Absence of cortical stroke and large subcortical stroke (recent or remote). EXCLUSION: To be eligible for entry into the study, the patient must not meet any of the criteria listed below: Disabling stroke (Modified Rankin Scale less than or equal to 4) Previous intracranial hemorrhage (excluding traumatic) or hemorrhagic stroke Age under 30 years High risk of bleeding (e.g. recurrent GI or GU bleeding, active peptic ulcer disease, etc) Anticipated requirement for long-term use of anticoagulants (e.g. recurrent DVT) or other antiplatelets Prior cortical stroke (diagnosed either clinically or by neuroimaging), or prior cortical or retinal TIA Prior ipsilateral carotid endarterectomy Impaired renal function: GFR <40 Intolerance or contraindications to aspirin or clopidogrel (including thrombocytopenia, prolonged INR) A score < 24 (adjusted for age and education) on the Folstein Mini Mental Status Examination Medical contraindication to MRI Pregnancy or women of child-bearing potential who are not following an effective method of contraception Geographic or social factors making study participation impractical Unable or unwilling to provide informed consent Unlikely to be compliant with therapy/unwilling to return for frequent clinic visits Patients concurrently participating in another study with an investigational drug or device Other likely specific cause of stroke (e.g. dissection, vasculitis, prothrombotic diathesis, drug abuse)

Sites / Locations

  • University of Southern Alabama Stroke Center
  • Catholic Healthcare West
  • Mayo Clinic Scottsdale
  • University of Arizona, Department of Neurology
  • University of California San Diego Medical Center
  • University of California San Francisco-Fresno
  • Denver
  • Melbourne
  • Miami-University of Miami, Miller School of Medicine
  • Emory University, Grady Health System
  • Mercy Medical Center-Ruan Neurology Clinical Research
  • University of Kentucky, Aging/Stroke Program
  • Suburban Hospital
  • Boston University
  • Wayne State
  • Henry Ford Hospital, Department of Neurology
  • Berman Center
  • Mayo Stroke Center KA-SL-13
  • University of Washington
  • Tenet Health, St. Louis University
  • St. John's Mercy
  • Cooper University Hospital
  • Buffalo
  • Helen Hayes Hospital
  • Columbia University Medical Center
  • Rochester General Hospital
  • University of Rochester
  • Wake Forest University, Sciences-Neurology
  • Case Western
  • Metrohealth Medical Center
  • Ohio State University, Division of Stroke
  • Oregon Health and Science University
  • Vanderbilt University Medical Center
  • University of Texas Southwestern
  • Scurlock Stroke Center
  • University of Texas Health Science Center
  • University of Washington
  • Marshfield Clinic, Department of Neurology
  • Medical College of Wisconsin-Neurology
  • Calgary Health
  • SPS3 Coordinating Center
  • Halifax
  • Ottawa Hospital General Campus
  • Greenfield Park
  • McGill-Jewish General
  • McGill-Montreal General
  • CHA-Hospital de l'Enfant-Jesus
  • Hospital Clinico de la Universidad Católica de Chile
  • Hospital Naval Almirante Nef, 'Subida Alessandri s/n, Hall A, Oficina 9
  • Hospital-Clinica Kennedy
  • Hospital de La Universidad Autonoma de Nuevo Leon
  • Antiguo Hospital Civil de Guadalajara
  • Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zuibrán
  • Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez
  • Hospital Sabogal Essalud-Unidad de Investigacion
  • Hosp. Universitario Germans Trias I Pujol
  • Hospital Del Mar, Passeig Marítim 25-29
  • Hospital de la Santa Creu I Sant Pau, c/Sant Antoni Maria Claret, 167
  • Hospital del Sagrat Cor. Quinta de Salut I'Alianca, c/Viladomat 288
  • Hosp. Parc Tauli de Sabadell
  • Hosp. de Girona Dr. Josep Trueta
  • Hospital La Paz
  • Universidad de Santiago de Compostela, Facultad de Medicina y Odontologia

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Antiplatelet

Blood pressure

Arm Description

Participants receive aspirin + placebo OR aspirin + clopidogrel

The goal of the blood pressure aspect of this trial is to find out if lowering blood pressure after stroke helps to prevent recurrent stroke and preserves cognition.

Outcomes

Primary Outcome Measures

Evidence of clinically defined ischemic stroke (focal neurological deficits persisting for more than 24 hours) confirmed by non-investigational CT or MRI
Evidence of hemorrhagic stroke; a neurologic deficit associated with intraparenchymal or subarachnoid space lesion on CT/MRI or cerebral hemorrhage demonstrated by surgery or autopsy.

Secondary Outcome Measures

The difference in the rate of cognitive decline among SPS3 participants assigned to receive aspirin alone versus combination of aspirin and clopidogrel, assessed through repeated neuropsychological tests; and major vascular events.

Full Information

First Posted
April 23, 2003
Last Updated
April 2, 2013
Sponsor
University of British Columbia
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
search

1. Study Identification

Unique Protocol Identification Number
NCT00059306
Brief Title
Secondary Prevention of Small Subcortical Strokes Trial
Acronym
SPS3
Official Title
Secondary Prevention of Small Subcortical Strokes (SPS3) Trial
Study Type
Interventional

2. Study Status

Record Verification Date
April 2013
Overall Recruitment Status
Completed
Study Start Date
February 2003 (undefined)
Primary Completion Date
April 2012 (Actual)
Study Completion Date
April 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of British Columbia
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The goal of this study is to learn if combination antiplatelet therapy (aspirin and clopidogrel) is more effective than aspirin alone for the prevention of recurrent stroke and cognitive decline, and if intensive blood pressure control is associated with fewer recurrent strokes and cognitive decline. On July 21, 2011 the DSMB recommended terminating the anti platelet arm of the study due to an imbalance of overall and major non-CNS hemorrhagic SAE's and total deaths in the investigational anti platelet combination of aspirin + clopidogrel and an interim statistical analysis that demonstrated futility in the investigational anti platelet arm. It was recommended that patients be continued on standard care of aspirin mono therapy until their study close-out visit. Also, recommended the continuation and completion of the plood pressure arm following the protocol.
Detailed Description
Stroke is damage to the brain caused by problems in the blood vessels. Strokes often cause paralysis, loss of sensation and speech, and other problems. A lacunar or small Subcortical stroke affects the inner part of the brain causing small "pea sized" areas of damage due to blockage of small blood vessels within the brain. This multi-center study will recruit 3000 participants (20 percent of whom will be Hispanic) to find out if using aspirin and clopidogrel is more effective than using aspirin alone to prevent recurrent stroke in patients with lacunar stroke confirmed by MRI, and if lowering a patient's blood pressure below the usual limits will also help prevent recurrent stroke and maintain thinking ability. Both aspirin and clopidogrel are widely-used for blood clotting and stroke prevention. Investigators intend to find out if using the drugs together is more effective than using aspirin alone. Participants will be randomly assigned to one of 2 types of treatment: either aspirin alone or the combination of aspirin and clopidogrel. In addition, participants will be assigned to one of 2 groups of blood pressure control. The difference between the two groups is the target level of systolic blood pressure-either 130-149 or below 130. The goal of the blood pressure aspect of this trial is to find out if lowering blood pressure after stroke helps to prevent recurrent stroke and preserves cognition.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cerebrovascular Accident, Hypertension
Keywords
stroke, hypertension, high blood pressure, lacunar stroke, subcortical stroke, aspirin, clopidogrel

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
3020 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Antiplatelet
Arm Type
Active Comparator
Arm Description
Participants receive aspirin + placebo OR aspirin + clopidogrel
Arm Title
Blood pressure
Arm Type
Active Comparator
Arm Description
The goal of the blood pressure aspect of this trial is to find out if lowering blood pressure after stroke helps to prevent recurrent stroke and preserves cognition.
Intervention Type
Drug
Intervention Name(s)
aspirin
Intervention Description
Participants receive aspirin + placebo, specifically: aspirin (325 mg) with placebo (an inactive substance). Participants will take 1 of each pill a day until the end of the study.
Intervention Type
Drug
Intervention Name(s)
clopidogrel
Intervention Description
Participants will receive aspirin + clopidogrel, specifically: aspirin (325 mg) with clopidogrel (75 mg)-- Participants will take 1 of each pill a day until the end of the study.
Intervention Type
Other
Intervention Name(s)
Target of Blood Pressure
Intervention Description
Participants will be assigned to one of 2 groups of blood pressure control. The difference between the two groups is the target level of systolic blood pressure-either 130-149 mmHg or below 130 mmHg; to do so, the scientists will use medications that are already in the market for blood pressure management.
Intervention Type
Other
Intervention Name(s)
placebo
Intervention Description
an inactive substance
Primary Outcome Measure Information:
Title
Evidence of clinically defined ischemic stroke (focal neurological deficits persisting for more than 24 hours) confirmed by non-investigational CT or MRI
Time Frame
Mean follow up of 4 years
Title
Evidence of hemorrhagic stroke; a neurologic deficit associated with intraparenchymal or subarachnoid space lesion on CT/MRI or cerebral hemorrhage demonstrated by surgery or autopsy.
Time Frame
within mean follow-up of 4 years
Secondary Outcome Measure Information:
Title
The difference in the rate of cognitive decline among SPS3 participants assigned to receive aspirin alone versus combination of aspirin and clopidogrel, assessed through repeated neuropsychological tests; and major vascular events.
Time Frame
within mean follow-up of 4 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
INCLUSION: Small subcortical ischemic stroke or subcortical TIA. Inclusion criteria are based on TOAST criteria supplemented by required MRI data. All of the following criteria must be met: One of the lacunar stroke clinical syndromes (adapted from Fisher) lasting > 24 hrs within the past 6 months Absence of signs or symptoms of cortical dysfunction such as aphasia, apraxia, agnosia, agraphia, homonymous visual field defect, etc. No ipsilateral cervical carotid stenosis (≥50%) by a reliable imaging modality done in an approved laboratory since the qualifying small subcortical stroke (S3), if hemispheric. No major-risk cardioembolic sources requiring anticoagulation or other specific therapy. Minor-risk cardioembolic sources will be permitted if anticoagulation is not prescribed by the patient's primary care physician. Subcortical TIA with corresponding lesion on DWI. MRI evidence of S3: a. Presence of an S3 (1.5 and 2 cm in diameter corresponding to the qualifying event on DWI; when TIA, ADC image must confirm lesion or T2/FLAIR (hyperintense lesions) (required for all brainstem events) OR multiple S3s on FLAIR/TI(<1.5 cm in diameter) (hypointense lesions) b. Absence of cortical stroke and large subcortical stroke (recent or remote). EXCLUSION: To be eligible for entry into the study, the patient must not meet any of the criteria listed below: Disabling stroke (Modified Rankin Scale less than or equal to 4) Previous intracranial hemorrhage (excluding traumatic) or hemorrhagic stroke Age under 30 years High risk of bleeding (e.g. recurrent GI or GU bleeding, active peptic ulcer disease, etc) Anticipated requirement for long-term use of anticoagulants (e.g. recurrent DVT) or other antiplatelets Prior cortical stroke (diagnosed either clinically or by neuroimaging), or prior cortical or retinal TIA Prior ipsilateral carotid endarterectomy Impaired renal function: GFR <40 Intolerance or contraindications to aspirin or clopidogrel (including thrombocytopenia, prolonged INR) A score < 24 (adjusted for age and education) on the Folstein Mini Mental Status Examination Medical contraindication to MRI Pregnancy or women of child-bearing potential who are not following an effective method of contraception Geographic or social factors making study participation impractical Unable or unwilling to provide informed consent Unlikely to be compliant with therapy/unwilling to return for frequent clinic visits Patients concurrently participating in another study with an investigational drug or device Other likely specific cause of stroke (e.g. dissection, vasculitis, prothrombotic diathesis, drug abuse)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Oscar Benavente, M.D.
Organizational Affiliation
University of British Columbia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Robert Hart, M.D.
Organizational Affiliation
McMaster University
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Southern Alabama Stroke Center
City
Mobile
State/Province
Alabama
ZIP/Postal Code
36617
Country
United States
Facility Name
Catholic Healthcare West
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85013
Country
United States
Facility Name
Mayo Clinic Scottsdale
City
Scottsdale
State/Province
Arizona
ZIP/Postal Code
85259
Country
United States
Facility Name
University of Arizona, Department of Neurology
City
Tucson
State/Province
Arizona
ZIP/Postal Code
85724
Country
United States
Facility Name
University of California San Diego Medical Center
City
San Diego
State/Province
California
ZIP/Postal Code
92103-8466
Country
United States
Facility Name
University of California San Francisco-Fresno
City
San Francisco-Fresno
State/Province
California
Country
United States
Facility Name
Denver
City
Englewood
State/Province
Colorado
Country
United States
Facility Name
Melbourne
City
Melbourne
State/Province
Florida
Country
United States
Facility Name
Miami-University of Miami, Miller School of Medicine
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Facility Name
Emory University, Grady Health System
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30303
Country
United States
Facility Name
Mercy Medical Center-Ruan Neurology Clinical Research
City
Des Moines
State/Province
Iowa
ZIP/Postal Code
50314
Country
United States
Facility Name
University of Kentucky, Aging/Stroke Program
City
Lexington
State/Province
Kentucky
ZIP/Postal Code
40506-0230
Country
United States
Facility Name
Suburban Hospital
City
Bethesda
State/Province
Maryland
Country
United States
Facility Name
Boston University
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02118
Country
United States
Facility Name
Wayne State
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Facility Name
Henry Ford Hospital, Department of Neurology
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Facility Name
Berman Center
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55404
Country
United States
Facility Name
Mayo Stroke Center KA-SL-13
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
University of Washington
City
Sant Louis
State/Province
Missouri
Country
United States
Facility Name
Tenet Health, St. Louis University
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
St. John's Mercy
City
St. Louis
State/Province
Missouri
ZIP/Postal Code
63141
Country
United States
Facility Name
Cooper University Hospital
City
Camden
State/Province
New Jersey
ZIP/Postal Code
08103
Country
United States
Facility Name
Buffalo
City
Buffalo
State/Province
New York
Country
United States
Facility Name
Helen Hayes Hospital
City
Haverstraw
State/Province
New York
ZIP/Postal Code
10993
Country
United States
Facility Name
Columbia University Medical Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Facility Name
Rochester General Hospital
City
Rochester
State/Province
New York
ZIP/Postal Code
14621
Country
United States
Facility Name
University of Rochester
City
Rochester
State/Province
New York
ZIP/Postal Code
14642
Country
United States
Facility Name
Wake Forest University, Sciences-Neurology
City
Winston-Salem
State/Province
North Carolina
ZIP/Postal Code
27157-1078
Country
United States
Facility Name
Case Western
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44106
Country
United States
Facility Name
Metrohealth Medical Center
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44109
Country
United States
Facility Name
Ohio State University, Division of Stroke
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Facility Name
Oregon Health and Science University
City
Portland
State/Province
Oregon
ZIP/Postal Code
97239
Country
United States
Facility Name
Vanderbilt University Medical Center
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States
Facility Name
University of Texas Southwestern
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390-8897
Country
United States
Facility Name
Scurlock Stroke Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Facility Name
University of Texas Health Science Center
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229-3900
Country
United States
Facility Name
University of Washington
City
Seattle
State/Province
Washington
ZIP/Postal Code
98104-2499
Country
United States
Facility Name
Marshfield Clinic, Department of Neurology
City
Marshfield
State/Province
Wisconsin
ZIP/Postal Code
54449
Country
United States
Facility Name
Medical College of Wisconsin-Neurology
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
Facility Name
Calgary Health
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N 2T9
Country
Canada
Facility Name
SPS3 Coordinating Center
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V6T 2B5
Country
Canada
Facility Name
Halifax
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3H 4V7
Country
Canada
Facility Name
Ottawa Hospital General Campus
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1H 8L6
Country
Canada
Facility Name
Greenfield Park
City
Greenfield Park
State/Province
Quebec
ZIP/Postal Code
J4V 2H1
Country
Canada
Facility Name
McGill-Jewish General
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H37 1E2
Country
Canada
Facility Name
McGill-Montreal General
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3G 1A4
Country
Canada
Facility Name
CHA-Hospital de l'Enfant-Jesus
City
Quebec City
State/Province
Quebec
ZIP/Postal Code
G1J 1Z4
Country
Canada
Facility Name
Hospital Clinico de la Universidad Católica de Chile
City
Santiago
Country
Chile
Facility Name
Hospital Naval Almirante Nef, 'Subida Alessandri s/n, Hall A, Oficina 9
City
Viña del Mar
ZIP/Postal Code
2530116
Country
Chile
Facility Name
Hospital-Clinica Kennedy
City
Guayaquil
Country
Ecuador
Facility Name
Hospital de La Universidad Autonoma de Nuevo Leon
City
Monterrey
State/Province
Nuevo Leon
ZIP/Postal Code
644460
Country
Mexico
Facility Name
Antiguo Hospital Civil de Guadalajara
City
Guadalajara
ZIP/Postal Code
44280
Country
Mexico
Facility Name
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zuibrán
City
Mexico City
ZIP/Postal Code
14000
Country
Mexico
Facility Name
Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez
City
Mexico City
ZIP/Postal Code
14269
Country
Mexico
Facility Name
Hospital Sabogal Essalud-Unidad de Investigacion
City
Bellavista-Callao
State/Province
Lima
Country
Peru
Facility Name
Hosp. Universitario Germans Trias I Pujol
City
Badalona
ZIP/Postal Code
08916
Country
Spain
Facility Name
Hospital Del Mar, Passeig Marítim 25-29
City
Barcelona
ZIP/Postal Code
08003
Country
Spain
Facility Name
Hospital de la Santa Creu I Sant Pau, c/Sant Antoni Maria Claret, 167
City
Barcelona
ZIP/Postal Code
08025
Country
Spain
Facility Name
Hospital del Sagrat Cor. Quinta de Salut I'Alianca, c/Viladomat 288
City
Barcelona
ZIP/Postal Code
08029
Country
Spain
Facility Name
Hosp. Parc Tauli de Sabadell
City
Barcelona
ZIP/Postal Code
08208
Country
Spain
Facility Name
Hosp. de Girona Dr. Josep Trueta
City
Girona
ZIP/Postal Code
17007
Country
Spain
Facility Name
Hospital La Paz
City
Madrid
ZIP/Postal Code
28046
Country
Spain
Facility Name
Universidad de Santiago de Compostela, Facultad de Medicina y Odontologia
City
Santiago de Compostela
ZIP/Postal Code
15782
Country
Spain

12. IPD Sharing Statement

Citations:
PubMed Identifier
36398903
Citation
Saiz LC, Gorricho J, Garjon J, Celaya MC, Erviti J, Leache L. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Cochrane Database Syst Rev. 2022 Nov 18;11(11):CD010315. doi: 10.1002/14651858.CD010315.pub5.
Results Reference
derived
PubMed Identifier
35224730
Citation
Natale P, Palmer SC, Saglimbene VM, Ruospo M, Razavian M, Craig JC, Jardine MJ, Webster AC, Strippoli GF. Antiplatelet agents for chronic kidney disease. Cochrane Database Syst Rev. 2022 Feb 28;2(2):CD008834. doi: 10.1002/14651858.CD008834.pub4.
Results Reference
derived
PubMed Identifier
35114798
Citation
Shihab S, Boucher RE, Abraham N, Wei G, Beddhu S. Influence of Baseline Diastolic Blood Pressure on the Effects of Intensive Systolic Blood Pressure Lowering on the Risk of Stroke. Hypertension. 2022 Apr;79(4):785-793. doi: 10.1161/HYPERTENSIONAHA.121.18172. Epub 2022 Feb 4.
Results Reference
derived
PubMed Identifier
33481011
Citation
Cukierman-Yaffe T, McClure LA, Risoli T, Bosch J, Sharma M, Gerstein HC, Benavente O. The Relationship Between Glucose Control and Cognitive Function in People With Diabetes After a Lacunar Stroke. J Clin Endocrinol Metab. 2021 Mar 25;106(4):e1521-e1528. doi: 10.1210/clinem/dgab022.
Results Reference
derived
PubMed Identifier
32905623
Citation
Saiz LC, Gorricho J, Garjon J, Celaya MC, Erviti J, Leache L. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Cochrane Database Syst Rev. 2020 Sep 9;9(9):CD010315. doi: 10.1002/14651858.CD010315.pub4.
Results Reference
derived
PubMed Identifier
32371759
Citation
Blum MR, Scherzer R, Ikeme JC, Benavente OR, McClure LA, Peralta CA, Odden MC. Functional health and white matter hyperintensities as effect modifiers of blood pressure-lowering on cognitive function and vascular events in older Secondary Prevention of Small Subcortical Strokes trial participants. J Hypertens. 2020 Aug;38(8):1578-1585. doi: 10.1097/HJH.0000000000002440.
Results Reference
derived
PubMed Identifier
31423869
Citation
Agarwal A, Cheung AK, Ma J, Cho M, Li M. Effect of Baseline Kidney Function on the Risk of Recurrent Stroke and on Effects of Intensive Blood Pressure Control in Patients With Previous Lacunar Stroke: A Post Hoc Analysis of the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes). J Am Heart Assoc. 2019 Aug 20;8(16):e013098. doi: 10.1161/JAHA.119.013098. Epub 2019 Aug 19.
Results Reference
derived
PubMed Identifier
30686103
Citation
Ikeme JC, Pergola PE, Scherzer R, Shlipak MG, Catanese L, McClure LA, Benavente OR, Peralta CA. Cerebral White Matter Hyperintensities, Kidney Function Decline, and Recurrent Stroke After Intensive Blood Pressure Lowering: Results From the Secondary Prevention of Small Subcortical Strokes ( SPS 3) Trial. J Am Heart Assoc. 2019 Feb 5;8(3):e010091. doi: 10.1161/JAHA.118.010091.
Results Reference
derived
PubMed Identifier
28351962
Citation
Magvanjav O, McDonough CW, Gong Y, McClure LA, Talbert RL, Horenstein RB, Shuldiner AR, Benavente OR, Mitchell BD, Johnson JA; NINDS SiGN (Stroke Genetics Network). Pharmacogenetic Associations of beta1-Adrenergic Receptor Polymorphisms With Cardiovascular Outcomes in the SPS3 Trial (Secondary Prevention of Small Subcortical Strokes). Stroke. 2017 May;48(5):1337-1343. doi: 10.1161/STROKEAHA.116.015936. Epub 2017 Mar 28.
Results Reference
derived
PubMed Identifier
26956031
Citation
Wilson LK, Pearce LA, Arauz A, Anderson DC, Tapia J, Bazan C, Benavente OR, Field TS; SPS3 Investigators. Morphological classification of penetrating artery pontine infarcts and association with risk factors and prognosis: The SPS3 trial. Int J Stroke. 2016 Jun;11(4):412-9. doi: 10.1177/1747493016637366. Epub 2016 Mar 8.
Results Reference
derived
PubMed Identifier
26888535
Citation
Boehme AK, McClure LA, Zhang Y, Luna JM, Del Brutto OH, Benavente OR, Elkind MS. Inflammatory Markers and Outcomes After Lacunar Stroke: Levels of Inflammatory Markers in Treatment of Stroke Study. Stroke. 2016 Mar;47(3):659-67. doi: 10.1161/STROKEAHA.115.012166.
Results Reference
derived
PubMed Identifier
26762524
Citation
Peralta CA, McClure LA, Scherzer R, Odden MC, White CL, Shlipak M, Benavente O, Pergola P. Effect of Intensive Versus Usual Blood Pressure Control on Kidney Function Among Individuals With Prior Lacunar Stroke: A Post Hoc Analysis of the Secondary Prevention of Small Subcortical Strokes (SPS3) Randomized Trial. Circulation. 2016 Feb 9;133(6):584-91. doi: 10.1161/CIRCULATIONAHA.115.019657. Epub 2016 Jan 13.
Results Reference
derived
PubMed Identifier
26553236
Citation
Odden MC, McClure LA, Sawaya BP, White CL, Peralta CA, Field TS, Hart RG, Benavente OR, Pergola PE. Achieved Blood Pressure and Outcomes in the Secondary Prevention of Small Subcortical Strokes Trial. Hypertension. 2016 Jan;67(1):63-9. doi: 10.1161/HYPERTENSIONAHA.115.06480. Epub 2015 Nov 9.
Results Reference
derived
PubMed Identifier
26019129
Citation
McDonough CW, McClure LA, Mitchell BD, Gong Y, Horenstein RB, Lewis JP, Field TS, Talbert RL, Benavente OR, Johnson JA, Shuldiner AR. CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study. J Am Heart Assoc. 2015 May 27;4(6):e001652. doi: 10.1161/JAHA.114.001652.
Results Reference
derived
PubMed Identifier
25453457
Citation
Pearce LA, McClure LA, Anderson DC, Jacova C, Sharma M, Hart RG, Benavente OR; SPS3 Investigators. Effects of long-term blood pressure lowering and dual antiplatelet treatment on cognitive function in patients with recent lacunar stroke: a secondary analysis from the SPS3 randomised trial. Lancet Neurol. 2014 Dec;13(12):1177-85. doi: 10.1016/S1474-4422(14)70224-8. Epub 2014 Oct 23.
Results Reference
derived
PubMed Identifier
25452300
Citation
Field TS, McClure LA, White CL, Pergola PE, Hart RG, Benavente OR, Hill MD; SPS3 Investigators. Should Blood Pressure Targets After Lacunar Stroke Vary by Body Size? The SPS3 Trial. Am J Hypertens. 2015 Jun;28(6):756-64. doi: 10.1093/ajh/hpu228. Epub 2014 Dec 1.
Results Reference
derived
PubMed Identifier
25190442
Citation
Asdaghi N, Pearce LA, Nakajima M, Field TS, Bazan C, Cermeno F, McClure LA, Anderson DC, Hart RG, Benavente OR; SPS3 Investigators. Clinical correlates of infarct shape and volume in lacunar strokes: the Secondary Prevention of Small Subcortical Strokes trial. Stroke. 2014 Oct;45(10):2952-8. doi: 10.1161/STROKEAHA.114.005211. Epub 2014 Sep 4.
Results Reference
derived
PubMed Identifier
25158772
Citation
Sharma M, Pearce LA, Benavente OR, Anderson DC, Connolly SJ, Palacio S, Coffey CS, Hart RG. Predictors of mortality in patients with lacunar stroke in the secondary prevention of small subcortical strokes trial. Stroke. 2014 Oct;45(10):2989-94. doi: 10.1161/STROKEAHA.114.005789. Epub 2014 Aug 26.
Results Reference
derived
PubMed Identifier
25034716
Citation
Palacio S, McClure LA, Benavente OR, Bazan C 3rd, Pergola P, Hart RG. Lacunar strokes in patients with diabetes mellitus: risk factors, infarct location, and prognosis: the secondary prevention of small subcortical strokes study. Stroke. 2014 Sep;45(9):2689-94. doi: 10.1161/STROKEAHA.114.005018. Epub 2014 Jul 17.
Results Reference
derived
PubMed Identifier
24862645
Citation
Benavente OR, Pearce LA, Bazan C, Roldan AM, Catanese L, Bhat Livezey VM, Vidal-Pergola G, McClure LA, Hart RG; SPS3 Investigators. Clinical-MRI correlations in a multiethnic cohort with recent lacunar stroke: the SPS3 trial. Int J Stroke. 2014 Dec;9(8):1057-64. doi: 10.1111/ijs.12282. Epub 2014 May 27.
Results Reference
derived
PubMed Identifier
24661819
Citation
Lewis BL, Pearce LA, Field TS, White CL, Benavente OR; SPS3 Investigators. The relevance of living supports on antiplatelet adherence and trial participation: the SPS3 trial. Int J Stroke. 2014 Jun;9(4):443-8. doi: 10.1111/ijs.12267. Epub 2014 Mar 24.
Results Reference
derived
PubMed Identifier
24523037
Citation
Elkind MS, Luna JM, McClure LA, Zhang Y, Coffey CS, Roldan A, Del Brutto OH, Pretell EJ, Pettigrew LC, Meyer BC, Tapia J, White C, Benavente OR; LIMITS Investigators. C-reactive protein as a prognostic marker after lacunar stroke: levels of inflammatory markers in the treatment of stroke study. Stroke. 2014 Mar;45(3):707-16. doi: 10.1161/STROKEAHA.113.004562. Epub 2014 Feb 12.
Results Reference
derived
PubMed Identifier
24177006
Citation
Dhamoon MS, McClure LA, White CL, Lau H, Benavente O, Elkind MS. Quality of life after lacunar stroke: the Secondary Prevention of Small Subcortical Strokes study. J Stroke Cerebrovasc Dis. 2014 May-Jun;23(5):1131-7. doi: 10.1016/j.jstrokecerebrovasdis.2013.09.029. Epub 2013 Oct 28.
Results Reference
derived
PubMed Identifier
23736109
Citation
White CL, Pergola PE, Szychowski JM, Talbert R, Cervantes-Arriaga A, Clark HD, Del Brutto OH, Godoy IE, Hill MD, Pelegri A, Sussman CR, Taylor AA, Valdivia J, Anderson DC, Conwit R, Benavente OR; SPS3 Investigators. Blood pressure after recent stroke: baseline findings from the secondary prevention of small subcortical strokes trial. Am J Hypertens. 2013 Sep;26(9):1114-22. doi: 10.1093/ajh/hpt076. Epub 2013 Jun 4.
Results Reference
derived
PubMed Identifier
23726159
Citation
SPS3 Study Group; Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, Pergola PE, Szychowski JM. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013 Aug 10;382(9891):507-15. doi: 10.1016/S0140-6736(13)60852-1. Epub 2013 May 29. Erratum In: Lancet. 2013 Aug 10;382(9891):506. Coffey, C S [aded].
Results Reference
derived
PubMed Identifier
23034910
Citation
Jacova C, Pearce LA, Costello R, McClure LA, Holliday SL, Hart RG, Benavente OR. Cognitive impairment in lacunar strokes: the SPS3 trial. Ann Neurol. 2012 Sep;72(3):351-62. doi: 10.1002/ana.23733.
Results Reference
derived
PubMed Identifier
22931315
Citation
SPS3 Investigators; Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med. 2012 Aug 30;367(9):817-25. doi: 10.1056/NEJMoa1204133.
Results Reference
derived
PubMed Identifier
22826359
Citation
Palacio S, Hart RG, Pearce LA, Benavente OR. Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials. Stroke. 2012 Aug;43(8):2157-62. doi: 10.1161/STROKEAHA.112.656173.
Results Reference
derived
PubMed Identifier
22750086
Citation
McClure LA, Szychowski JM, Benavente O, Coffey CS. Sample size re-estimation in an on-going NIH-sponsored clinical trial: the secondary prevention of small subcortical strokes experience. Contemp Clin Trials. 2012 Sep;33(5):1088-93. doi: 10.1016/j.cct.2012.06.007. Epub 2012 Jun 30.
Results Reference
derived
PubMed Identifier
22499292
Citation
Graves JW, White CL, Szychowski JM, Pergola PE, Benavente OR, Coffey CS, Hornung LN, Hart RG; SPS3 Study Investigators. Predictors of lowering SBP to assigned targets at 12 months in the Secondary Prevention of Small Subcortical Strokes study. J Hypertens. 2012 Jun;30(6):1233-40. doi: 10.1097/HJH.0b013e328353968d.
Results Reference
derived
PubMed Identifier
21899409
Citation
Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF, Hoh BL, Hourihane JM, Levy EI, Alexandrov AV, Harrigan MR, Chiu D, Klucznik RP, Clark JM, McDougall CG, Johnson MD, Pride GL Jr, Torbey MT, Zaidat OO, Rumboldt Z, Cloft HJ; SAMMPRIS Trial Investigators. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011 Sep 15;365(11):993-1003. doi: 10.1056/NEJMoa1105335. Epub 2011 Sep 7. Erratum In: N Engl J Med. 2012 Jul 5;367(1):93.
Results Reference
derived
PubMed Identifier
21371282
Citation
Benavente OR, White CL, Pearce L, Pergola P, Roldan A, Benavente MF, Coffey C, McClure LA, Szychowski JM, Conwit R, Heberling PA, Howard G, Bazan C, Vidal-Pergola G, Talbert R, Hart RG; SPS3 Investigators. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int J Stroke. 2011 Apr;6(2):164-75. doi: 10.1111/j.1747-4949.2010.00573.x. Epub 2011 Jan 26.
Results Reference
derived
PubMed Identifier
20446946
Citation
Elkind MS, Luna JM, Coffey CS, McClure LA, Liu KM, Spitalnik S, Paik MC, Roldan A, White C, Hart R, Benavente O. The Levels of Inflammatory Markers in the Treatment of Stroke study (LIMITS): inflammatory biomarkers as risk predictors after lacunar stroke. Int J Stroke. 2010 Apr;5(2):117-25. doi: 10.1111/j.1747-4949.2010.00420.x.
Results Reference
derived
Links:
URL
http://sps3.med.ubc.ca/
Description
Related Info
URL
http://www.nlm.nih.gov/databases/alerts/2011_ninds_stroke.html
Description
Related Info

Learn more about this trial

Secondary Prevention of Small Subcortical Strokes Trial

We'll reach out to this number within 24 hrs